The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma

Fu Tsai Chung, Ming Yun Ho, Yueh Fu Fang, Meng Heng Hshieh, Tsai Yu Wang, Chih Hsi Kuo, Hao Cheng Chen, Chun Hwa Wang, Shu Min Lin, Chih Teng Yu, Horng Chyuan Lin, Han Pin Kuo

Research output: Contribution to journalArticle

Abstract

Objectives. Chemotherapy as first-/second-line treatment in different epidermal growth factor receptor (EGFR) mutation lung adenocarcinoma remains controversial. Methods. Consecutive patients were collected between 2009 and 2012. Patients were divided into two groups (1st-line chemotherapy: n = 56 and 2nd-line chemotherapy: n = 55). Their outcomes profiles were analyzed. Results. The overall survival (OS) of all patients (390 versus 662 days, p < 0.0001), as well as both progression-free survival (PFS, 151 versus 252 days, p = 0.0001) and OS (308 versus 704 days, p = 0.0001) of patients with L858R mutation (n = 63), who received 2nd-line chemotherapy, was significantly poor. By univariate and multivariate analysis, 2nd-line chemotherapy, and L858R mutation were significantly related to poor PFS and OS. Conclusion. In advanced lung adenocarcinoma, L858R mutation and 2nd-line chemotherapy caused a poor outcome. It is a consideration to choice of 1st-line chemotherapy in these subjects. A prospective design is warranted to confirm this finding.

Original languageEnglish
Article number948267
JournalBioMed Research International
Volume2015
DOIs
Publication statusPublished - Jan 1 2015
Externally publishedYes

Fingerprint

Chemotherapy
Epidermal Growth Factor Receptor
Drug Therapy
Mutation
Therapeutics
Survival
Adenocarcinoma of lung
Disease-Free Survival
Multivariate Analysis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma. / Chung, Fu Tsai; Ho, Ming Yun; Fang, Yueh Fu; Hshieh, Meng Heng; Wang, Tsai Yu; Kuo, Chih Hsi; Chen, Hao Cheng; Wang, Chun Hwa; Lin, Shu Min; Yu, Chih Teng; Lin, Horng Chyuan; Kuo, Han Pin.

In: BioMed Research International, Vol. 2015, 948267, 01.01.2015.

Research output: Contribution to journalArticle

Chung, FT, Ho, MY, Fang, YF, Hshieh, MH, Wang, TY, Kuo, CH, Chen, HC, Wang, CH, Lin, SM, Yu, CT, Lin, HC & Kuo, HP 2015, 'The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma', BioMed Research International, vol. 2015, 948267. https://doi.org/10.1155/2015/948267
Chung, Fu Tsai ; Ho, Ming Yun ; Fang, Yueh Fu ; Hshieh, Meng Heng ; Wang, Tsai Yu ; Kuo, Chih Hsi ; Chen, Hao Cheng ; Wang, Chun Hwa ; Lin, Shu Min ; Yu, Chih Teng ; Lin, Horng Chyuan ; Kuo, Han Pin. / The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma. In: BioMed Research International. 2015 ; Vol. 2015.
@article{758a5ebcd48f4c049e6902859f202512,
title = "The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma",
abstract = "Objectives. Chemotherapy as first-/second-line treatment in different epidermal growth factor receptor (EGFR) mutation lung adenocarcinoma remains controversial. Methods. Consecutive patients were collected between 2009 and 2012. Patients were divided into two groups (1st-line chemotherapy: n = 56 and 2nd-line chemotherapy: n = 55). Their outcomes profiles were analyzed. Results. The overall survival (OS) of all patients (390 versus 662 days, p < 0.0001), as well as both progression-free survival (PFS, 151 versus 252 days, p = 0.0001) and OS (308 versus 704 days, p = 0.0001) of patients with L858R mutation (n = 63), who received 2nd-line chemotherapy, was significantly poor. By univariate and multivariate analysis, 2nd-line chemotherapy, and L858R mutation were significantly related to poor PFS and OS. Conclusion. In advanced lung adenocarcinoma, L858R mutation and 2nd-line chemotherapy caused a poor outcome. It is a consideration to choice of 1st-line chemotherapy in these subjects. A prospective design is warranted to confirm this finding.",
author = "Chung, {Fu Tsai} and Ho, {Ming Yun} and Fang, {Yueh Fu} and Hshieh, {Meng Heng} and Wang, {Tsai Yu} and Kuo, {Chih Hsi} and Chen, {Hao Cheng} and Wang, {Chun Hwa} and Lin, {Shu Min} and Yu, {Chih Teng} and Lin, {Horng Chyuan} and Kuo, {Han Pin}",
year = "2015",
month = "1",
day = "1",
doi = "10.1155/2015/948267",
language = "English",
volume = "2015",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma

AU - Chung, Fu Tsai

AU - Ho, Ming Yun

AU - Fang, Yueh Fu

AU - Hshieh, Meng Heng

AU - Wang, Tsai Yu

AU - Kuo, Chih Hsi

AU - Chen, Hao Cheng

AU - Wang, Chun Hwa

AU - Lin, Shu Min

AU - Yu, Chih Teng

AU - Lin, Horng Chyuan

AU - Kuo, Han Pin

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objectives. Chemotherapy as first-/second-line treatment in different epidermal growth factor receptor (EGFR) mutation lung adenocarcinoma remains controversial. Methods. Consecutive patients were collected between 2009 and 2012. Patients were divided into two groups (1st-line chemotherapy: n = 56 and 2nd-line chemotherapy: n = 55). Their outcomes profiles were analyzed. Results. The overall survival (OS) of all patients (390 versus 662 days, p < 0.0001), as well as both progression-free survival (PFS, 151 versus 252 days, p = 0.0001) and OS (308 versus 704 days, p = 0.0001) of patients with L858R mutation (n = 63), who received 2nd-line chemotherapy, was significantly poor. By univariate and multivariate analysis, 2nd-line chemotherapy, and L858R mutation were significantly related to poor PFS and OS. Conclusion. In advanced lung adenocarcinoma, L858R mutation and 2nd-line chemotherapy caused a poor outcome. It is a consideration to choice of 1st-line chemotherapy in these subjects. A prospective design is warranted to confirm this finding.

AB - Objectives. Chemotherapy as first-/second-line treatment in different epidermal growth factor receptor (EGFR) mutation lung adenocarcinoma remains controversial. Methods. Consecutive patients were collected between 2009 and 2012. Patients were divided into two groups (1st-line chemotherapy: n = 56 and 2nd-line chemotherapy: n = 55). Their outcomes profiles were analyzed. Results. The overall survival (OS) of all patients (390 versus 662 days, p < 0.0001), as well as both progression-free survival (PFS, 151 versus 252 days, p = 0.0001) and OS (308 versus 704 days, p = 0.0001) of patients with L858R mutation (n = 63), who received 2nd-line chemotherapy, was significantly poor. By univariate and multivariate analysis, 2nd-line chemotherapy, and L858R mutation were significantly related to poor PFS and OS. Conclusion. In advanced lung adenocarcinoma, L858R mutation and 2nd-line chemotherapy caused a poor outcome. It is a consideration to choice of 1st-line chemotherapy in these subjects. A prospective design is warranted to confirm this finding.

UR - http://www.scopus.com/inward/record.url?scp=84947460037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947460037&partnerID=8YFLogxK

U2 - 10.1155/2015/948267

DO - 10.1155/2015/948267

M3 - Article

VL - 2015

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 948267

ER -